SR | MR | ER | ||||
---|---|---|---|---|---|---|
Resp. / n |
% 95% CI | Resp. / n |
% 95% CI | Resp. / n |
% 95% CI | |
Total data set (Ovarian cancer) Charité Berlin 2012 | 22/28 |
79 59–92 | 9/17 |
53 28–77 | 0/7 |
0 0–41 |
Total data set Kern DH, Weisenthal LM (1990) | 115/222 |
52 45–59 | 16/101 |
16 9–24 | 1/127 |
1 0–4 |
Ovarian cancer Kern DH, Weisenthal LM (1990) | 14/24 |
58 37–78 | 0/11 |
0 0–28 | 0/11 |
0 0–28 |
Single agent chemotherapy Kern DH, Weisenthal LM (1990) | 72/151 |
48 40–56 | 9/79 |
16 5–21 | 1/115 |
1 0–5 |
Single agent chemotherapy Charité Berlin 2012 | 4/9 |
44 14–79 | 2/6 |
33 4–78 | 0/4 |
0 0–60 |
Combination chemotherapy Kern DH, Weisenthal LM (1990) | 43/71 |
61 48–72 | 7/22 |
32 14–55 | 0/12 |
0 0–26 |
Combination chemotherapy Charité Berlin 2012 | 18/19 |
95 74–100 | 7/11 |
64 31–89 | 0/3 |
0 0–71 |